N※N

Women's Heart Disease Often Goes Undiagnosed: Why Symptom Differences Matter

85

  //health-fitness.news-articles.net/content/2025/ .. -undiagnosed-why-symptom-differences-matter.html
  Published in Health and Fitness on Saturday, December 13th 2025 at 5:39 GMT by TheHealthSite

• 🞛 This publication is a summary or evaluation of another publication
• 🞛 This publication contains editorial commentary or bias from the source

2025-12-13 179 x 224 / 10998 Bytes

2025-12-13 201 x 224 / 9049 Bytes

2025-12-13 224 x 224 / 7097 Bytes

2025-12-13 179 x 224 / 7497 Bytes

Why Heart Disease in Women Often Goes Undiagnosed – A Detailed Summary

Heart disease remains the leading cause of death for both men and women in the United States, yet women’s cardiac health is frequently overlooked. The Health Site’s feature, “Heart disease is often undiagnosed in women: here’s why their symptoms get overlooked,” pulls together medical research, clinical anecdotes, and public‑health data to explain why women are more likely to miss the diagnosis, and what steps can be taken to close this gap.

1. The Symptom Paradox

The most glaring reason for under‑diagnosis is the difference in symptom presentation between sexes. Classic chest‑pain‑on‑pressure is far less common in women. According to the article (linking to a 2023 study in Circulation), only 42 % of women who experienced an acute coronary syndrome reported classic angina, compared with 65 % of men. Instead, women more often report:

• Fatigue or general weakness
• Shortness of breath
• Indigestion or nausea
• Pain or pressure in the neck, jaw, back, or upper abdomen
• Sudden, unexplained dizziness or fainting

These “atypical” symptoms are easily dismissed as stress, menopause, or gastrointestinal disorders—especially when a clinician expects chest pain. The article cites a 2022 qualitative interview series with women who had been misdiagnosed; many recalled being told “you’re just nervous” or “that’s normal for women over 50.”

2. Diagnostic Bias and Risk Calculation

Even when symptoms prompt evaluation, risk calculators themselves can be gender‑biased. The most widely used tool, the Framingham Risk Score, was derived largely from male cohorts. The article links to the American Heart Association (AHA) guidelines, which now recommend the ASCVD (Atherosclerotic Cardiovascular Disease) risk estimator, but note that it too tends to under‑predict risk in women with non‑traditional risk factors.

Women often present with risk factors that aren’t fully captured: pregnancy‑related complications (preeclampsia, gestational diabetes), autoimmune diseases (lupus, rheumatoid arthritis), thyroid disorders, and hormonal shifts after menopause. These are listed in the article’s sidebar, which links to the NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases page on how autoimmune disease accelerates coronary artery disease.

3. The Microvascular and Subclinical Story

Beyond the “obstructive” plaque that men tend to develop, women are more likely to suffer from microvascular angina—blockages in the tiny coronary vessels that standard angiography misses. The article references a 2021 multicenter trial (linking to Journal of the American College of Cardiology) that showed microvascular dysfunction accounts for up to 50 % of heart‑attack‑like events in women. Because routine angiograms are designed to detect large‑vessel blockages, these cases often pass unnoticed, leading to a delayed or missed diagnosis.

Furthermore, women’s atherosclerosis is frequently less calcified, making it harder to detect on a standard chest X‑ray or basic ECG. The Health Site article explains that this “soft plaque” is invisible to some imaging modalities, necessitating advanced techniques like coronary CT angiography or cardiac MRI—often not the first line in most hospitals.

4. Under‑Representation in Clinical Trials

The article underscores a systemic problem: women are under‑represented in cardiac clinical trials. An AHA data table (link included in the article) shows that only 32 % of participants in recent drug‑approval trials were women, despite cardiovascular disease’s higher mortality in women after age 55. This under‑representation hampers the development of sex‑specific guidelines for drug dosing, timing of interventions, and post‑procedure rehabilitation.

5. Real‑World Consequences

The piece presents compelling statistics that illustrate the real‑world toll:

• Women are 1.4 times more likely than men to experience a delayed or missed diagnosis of heart disease.
• Women die an average of 9–10 days later after their first heart attack than men (source: JAMA Cardiology, 2022).
• The average age of women’s first heart attack is 10 years older than men’s, yet their risk factors are often the same or more severe.

These numbers are not just academic; they’re tied to a personal narrative from a woman who survived a heart attack only after persistent advocacy. Her story—shared in the article’s “Voices from the Frontlines” section—highlights how a single misdiagnosis can mean the difference between life and death.

6. What Can Be Done?

a. Heightened Awareness

The article offers practical advice for both patients and providers. Women should be educated to recognize their own “women‑specific” symptoms and communicate them clearly. Providers are urged to:

• Take detailed histories that include pregnancy complications, autoimmune disease, and thyroid status.
• Consider early referral for advanced imaging if classic risk calculators under‑estimate risk.

b. Screening Innovations

Linking to a WHO review, the article discusses newer screening tools like the Coronary Artery Calcium (CAC) score, which has shown higher predictive power for women who otherwise would be considered low risk by traditional scores.

c. Tailored Treatment Protocols

A highlighted study from the European Heart Journal shows that women respond differently to certain medications, like beta‑blockers and statins, especially at standard doses. The article stresses the need for sex‑specific dosing guidelines and encourages clinicians to monitor side‑effects closely.

d. Advocacy and Policy

The Health Site feature calls for national policy changes—mandating that all cardiovascular research include a minimum of 50 % female participants, and that insurance payers cover the more expensive, but necessary, diagnostic imaging for women with ambiguous symptoms.

7. Final Takeaway

Heart disease is a silent killer in women, largely because the medical system has historically been built around male symptom profiles and risk calculators. The Health Site article does more than highlight a problem—it lays out a multi‑layered strategy to catch heart disease early in women: better symptom awareness, improved risk assessment tools, more inclusive research, and policy‑level changes.

By following the linked resources—AHA’s guidelines, NIH’s research on autoimmune‑related cardiovascular risk, and peer‑reviewed studies on microvascular disease—readers can grasp the depth of the issue and the practical steps that are already being tested to reduce the under‑diagnosis gap.

In sum, women’s heart disease demands attention that is as nuanced and dynamic as the heart itself. The article urges both clinicians and patients to shift from a one‑size‑fits‑all mindset toward a sex‑specific, evidence‑based approach that could save thousands of lives each year.